263.50
-1.50
(-0.57%)
At close: 1:30:23 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Li Fang Pan | Chief Financial Officer and Manager of the Administrative Office | -- | -- | -- |
| Pei-Jiun Chen | Chief Operating Officer | -- | -- | -- |
| Jia Qi Yang | Financial Officer, Accounting Officer & Acting Spokesperson | -- | -- | -- |
| Todd Ban | Head of Business Development Division | -- | -- | -- |
Lumosa Therapeutics Co., Ltd.
No. 3-2, Park Street
4th Floor Nangang District
Taipei, 11503
Taiwan
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 47
Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Corporate Governance
Lumosa Therapeutics Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
4147.TWO TaiMed Biologics Inc.
86.50
+0.35%
6547.TWO Medigen Vaccine Biologics Corporation
47.60
-3.94%
6919.TW CALIWAY BIOPHARMACEUTICALS CO L
665.00
+3.74%
4743.TWO Oneness Biotech Co., Ltd.
79.70
+1.66%
4142.TW Adimmune Corporation
22.60
-1.74%
4162.TWO PharmaEngine, Inc.
95.10
+2.15%
4130.TWO Genovate Biotechnology Co., Ltd.
25.30
+1.81%
4726.TWO Mycenax Biotech Inc.
40.25
0.00%
6589.TWO EirGenix Inc.
79.80
+1.01%
3205.TWO Sagittarius Life Science Corp
33.95
-1.59%